RhuMAb IFNalpha ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	2

49. 全身性エリテマトーデス

---

臨床試験数 : 993 /  薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00962832 (ClinicalTrials.gov)	September 2009	19/8/2009	A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus	A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rontalizumab (rhuMAb IFNalpha) in Patients With Moderately to Severely Active Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: Placebo;Drug: Rontalizumab	Genentech, Inc.	NULL	Completed	18 Years	65 Years	Both	238	Phase 2	United States;Argentina;Colombia;Mexico;Poland;Russian Federation;United Kingdom
2	NCT00541749 (ClinicalTrials.gov)	February 2007	7/10/2007	A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus	A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: rhuMAb IFNalpha	Genentech, Inc.	NULL	Completed	18 Years	65 Years	Both	60	Phase 1	United States